Trials / Recruiting
RecruitingNCT06577753
REspiratory diSEAse cohoRt Studies of CHinese Medicine for ILD (RESEARCH-ILD)
REspiratory diSEAse cohoRt Studies of CHinese Medicine for Interstitial Lung Disease (RESEARCH-ILD)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 5,000 (estimated)
- Sponsor
- Henan University of Traditional Chinese Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This study is a traditional Chinese medicine cohort for interstitial lung disease(ILD) in China, including at least 5000 patients with ILD and followed up for at least 5 years. The aim is to focus on the demographic characteristics, clinical features, disease occurrence and development characteristics, TCM syndrome evolution patterns, and clinical efficacy of TCM treatment for ILD in the real world.
Detailed description
This study focuses on ILD patients and adopts a prospective cohort study design, with traditional Chinese medicine treatment as the exposure factor. The subjects are divided into a traditional Chinese medicine cohort and a non traditional Chinese medicine cohort, with demographic characteristics, mortality rate, lung transplant rate, annual acute exacerbation frequency, traditional Chinese medicine syndrome, 6MWT, lung function, dyspnea score, quality of life, and other observation indicators. Follow up for at least 5 years will be conducted, and at least 5000 ILD patients will be included, focusing on the demographic characteristics, clinical characteristics, disease occurrence and development characteristics, traditional Chinese medicine syndrome evolution rules, and clinical efficacy of traditional Chinese medicine treatment for ILD in the real world.
Conditions
Timeline
- Start date
- 2024-04-15
- Primary completion
- 2029-12-30
- Completion
- 2030-12-30
- First posted
- 2024-08-29
- Last updated
- 2024-08-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06577753. Inclusion in this directory is not an endorsement.